REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/13/2026
Back to search
Official data from USPTO
KHERION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KHERION
ST13
US500000079267807Class
5, 9, 42
Filing
79267807
Registration
6413425
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
07/13/2026
Trademark type
Word
Nice classes
5, 9, 42
Filing date
04/04/2019
Registration date
07/13/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/13/2021
Last transaction
07/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
KELLEY, EVELYN
Law office
N90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kherion Technology Limited
Representatives
John P. McCormick Fish & Richardson P.C.
Technical classification
Nice Classes
Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment and prevention of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disorderscardiovascular diseases or disordersmetabolic diseases or disordersinflammationcancerdiabetes; pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceuticalmedical and veterinary preparations and substances for the treatment and prevention of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disorderscardiovascular diseases or disordersmetabolic diseases or disordersinflammationcancerdiabetes; pharmaceuticalmedical and veterinary preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases or disorders; enzymes for medical and veterinary purposes; vaccines; diagnostic agentsreagentspreparations and substances for pharmaceuticalmedical and veterinary purposes; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersblood fraction proteins; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases or disordershuman plasma proteins; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersanimal plasma proteins; gene regulatory proteins for medical use; Biological preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersantibodies; antibody receptors for medical use; antigens for medical use; antigen receptors for medical use; sanitary preparations for medical and veterinary purposes; preparations for destroying vermin; fungicidesherbicides; molecular components and complexes for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders
Class 9
Electronic data in recorded form and downloadable electronic publications in the nature of reportsarticlese-books and e-zines relating to enzymesvaccinespharmaceuticals and pharmaceuticalmedical and veterinary preparations and substances
Class 42
Scientific and technological services and research and design relating thereto relating to enzymesvaccinespharmaceuticals and pharmaceuticalmedical and veterinary preparations and substances; research in the field of molecular biology; pharmaceuticalmedical and veterinary research; industrial analysis in the biologicalpharmaceuticalmedicalveterinary fields; industrial research services in the fields of pharmaceuticalsmedicine and science; researchdevelopmenttesting and evaluation of pharmaceuticals and of pharmaceuticalmedical and veterinary preparations and substances; researchdevelopmenttesting and evaluation of enzymes and of diagnostic agentsreagentspreparations and substances for pharmaceuticalmedical and veterinary purposes; provision of information and consultancy in relation to any of the aforesaid services
Publications
History of USPTO decisions and trademark events.
41 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/15/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/24/2021
FIMP
FINAL DISPOSITION PROCESSED
10/23/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/13/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/13/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/03/2021
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
04/27/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
04/17/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/17/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/13/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/24/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/24/2021
GPNX
NOTIFICATION PROCESSED BY IB
12/12/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
11/24/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/24/2020
PUBO
PUBLISHED FOR OPPOSITION
11/24/2020
GPNX
NOTIFICATION PROCESSED BY IB
11/21/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/04/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/04/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/19/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
10/16/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/16/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
10/16/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/16/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/27/2020
GNFR
FINAL REFUSAL E-MAILED
05/27/2020
CNFR
FINAL REFUSAL WRITTEN
05/27/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/28/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/28/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/28/2020
RFNT
REFUSAL PROCESSED BY IB
11/22/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/02/2019
RFRR
REFUSAL PROCESSED BY MPU
11/02/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/16/2019
CNRT
NON-FINAL ACTION WRITTEN
10/15/2019
MAFR
APPLICATION FILING RECEIPT MAILED
10/05/2019
DOCK
ASSIGNED TO EXAMINER
10/01/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/01/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/19/2019
Continuous trademark protection
Get notified about every new filing that threatens KHERION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.